Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes

Regulatory Peptides

Volumn 163, Issue 1-3, 2010, Pages 96-101

  Christensen, Mikkel ^a   Knop, Filip K ^a   Vilsbøll, Tina ^a   Aaboe, Kasper ^a,b   Holst, Jens J ^b   Madsbad, Sten ^a   Krarup, Thure ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Alpha cell; Diabetes; Glucagon; Glucagon like peptide 2 (GLP 2); Glucose dependent insulinotropic polypeptide (GIP); Incretin effect; Type 1 diabetes mellitus

Indexed keywords

ARGININE; C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; INSULIN; SODIUM CHLORIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DIET RESTRICTION; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HORMONE RESPONSE; HORMONE SUBSTITUTION; HUMAN; INFUSION; INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL; PARACRINE SIGNALING; POST HOC ANALYSIS; PRIORITY JOURNAL;

ADULT; DIABETES MELLITUS, TYPE 1; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 2; HUMANS; TIME FACTORS; YOUNG ADULT;

EID: 77953914489     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2010.05.004     Document Type: Article

References (32)

1. Gromada J., Franklin I., Wollheim C.B. Alpha-cells of the endocrine pancreas: 35years of research but the enigma remains. Endocr Rev 2007, 28(1):84-116.
2. Muller W.A., Faloona G.R., Aguilar-Parada E., Unger R.H. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1970, 283(3):109-115.
3. Ohneda A., Watanabe K., Horigome K., Sakai T., Kai Y., Oikawa S. Abnormal response of pancreatic glucagon to glycemic changes in diabetes mellitus. J Clin Endocrinol Metab 1978, 46(3):504-510.
4. Reaven G.M., Chen Y.D., Golay A., Swislocki A.L., Jaspan J.B. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987, 64(1):106-110.
5. Shah P., Vella A., Basu A., Basu R., Schwenk W.F., Rizza R.A. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000, 85(11):4053-4059.
6. Raskin P., Aydin I., Yamamoto T., Unger R.H. Abnormal alpha cell function in human diabetes: the response to oral protein. Am J Med 1978, 64(6):988-997.
7. Gutniak M., Grill V., Efendic S. Effect of composition of mixed meals-low- versus high-carbohydrate content-on insulin, glucagon, and somatostatin release in healthy humans and in patients with NIDDM. Diab Care 1986, 9(3):244-249.
8. Henkel E., Menschikowski M., Koehler C., Leonhardt W., Hanefeld M. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus. Metabolism 2005, 54(9):1168-1173.
9. Del Prato S., Marchetti P. Beta- and alpha-cell dysfunction in type 2 diabetes. Horm Metab Res 2004, 36(11-12):775-781.
10. Raju B., Cryer P.E. Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon?. Am J Physiol Endocrinol Metab 2005, 289(2):E181-E186.
11. Dunning B.E., Gerich J.E. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007, 28(3):253-283.
12. Firth R.G., Bell P.M., Marsh H.M., Hansen I., Rizza R.A. Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus. Role of hepatic and extrahepatic tissues. J Clin Invest 1986, 77(5):1525-1532.
13. Gerich J.E., Lorenzi M., Karam J.H., Schneider V., Forsham P.H. Abnormal pancreatic glucagon secretion and postprandial hyperglycemia in diabetes mellitus. JAMA 1975, 234(2):155-159.
14. Knop F.K., Vilsboll T., Madsbad S., Holst J.J., Krarup T. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 2007, 50(4):797-805.
15. Muscelli E., Mari A., Casolaro A., Camastra S., Seghieri G., Gastaldelli A., et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008, 57(5):1340-1348.
16. Meier J.J., Deacon C.F., Schmidt W.E., Holst J.J., Nauck M.A. Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. Diabetologia 2007, 50(4):806-813.
17. Creutzfeldt W.O., Kleine N., Willms B., Orskov C., Holst J.J., Nauck M.A. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diab Care 1996, 19(6):580-586.
18. Meier J.J., Gallwitz B., Siepmann N., Holst J.J., Deacon C.F., Schmidt W.E., et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003, 46(6):798-801.
19. Pederson R.A., Brown J.C. Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas. Endocrinology 1978, 103(2):610-615.
20. Vilsboll T., Knop F.K., Krarup T., Johansen A., Madsbad S., Larsen S., et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab 2003, 88(10):4897-4903.
21. de Heer J., Pedersen J., Orskov C., Holst J.J. The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas. Diabetologia 2007, 50(10):2135-2142.
22. Meier J.J., Nauck M.A., Pott A., Heinze K., Goetze O., Bulut K., et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 2006, 130(1):44-54.
23. Krarup T., Holst J.J. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regul Pept 1984, 9(1-2):35-46.
24. Deacon C.F., Nauck M.A., Meier J., Hucking K., Holst J.J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000, 85(10):3575-3581.
25. Hartmann B., Johnsen A.H., Orskov C., Adelhorst K., Thim L., Holst J.J. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides 2000, 21(1):73-80.
26. Orskov C., Jeppesen J., Madsbad S., Holst J.J. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 1991, 87(2):415-423.
27. Ahren B., Lundquist I. Glucagon immunoreactivity in plasma from normal and dystrophic mice. Diabetologia 1982, 22(4):258-263.
28. Hartmann B., Harr M.B., Jeppesen P.B., Wojdemann M., Deacon C.F., Mortensen P.B., et al. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 2000, 85(8):2884-2888.
29. Deacon C.F., Nauck M.A., Meier J., Hucking K., Holst J.J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000, 85(10):3575-3581.
30. Knop F.K., Vilsboll T., Larsen S., Hojberg P.V., Volund A., Madsbad S., et al. Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. Am J Physiol Endocrinol Metab 2007, 292(1):E324-E330.
31. Nauck M.A., Heimesaat M.M., Orskov C., Holst J.J., Ebert R., Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91(1):301-307.
32. Sorensen L.B., Flint A., Raben A., Hartmann B., Holst J.J., Astrup A. No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. Int J Obes Relat Metab Disord 2003, 27(4):450-456.